Why is methotrexate contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m²?

Why Methotrexate is Contraindicated Below GFR 60

Methotrexate should not be used when GFR is below 60 mL/min/1.73 m² because the drug is predominantly renally excreted, and impaired kidney function leads to drug accumulation, dramatically increasing the risk of life-threatening toxicities including myelosuppression, mucositis, and multi-organ failure.

The Pharmacokinetic Problem

Methotrexate is primarily eliminated through glomerular filtration and active tubular secretion in the kidneys 1. When renal function declines, the drug cannot be adequately cleared, leading to:

• Prolonged serum half-life and tissue accumulation
• Elevated drug concentrations even at standard low doses
• Unpredictable toxicity that may occur suddenly and severely

The FDA drug label explicitly warns that "methotrexate elimination is reduced in patients with impaired renal function" and such patients "require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation" 1.

The Evidence-Based Threshold

The KDIGO guidelines provide the clearest recommendation: methotrexate should be used for maintenance therapy in ANCA vasculitis "but not if GFR is <60 ml/min per 1.73 m²" (Grade 1C recommendation) 2, 3, 2. This threshold is consistently cited across multiple international nephrology guidelines.

The British Association of Dermatologists reinforces this with a more granular approach 4:

• GFR >90: Normal dosing
• GFR 20-50: Half dose only
• GFR <20: Avoid methotrexate completely

The Toxicity Profile in Renal Dysfunction

Real-world data demonstrates the clinical consequences of using methotrexate with reduced GFR:

• In a cohort of 120 RA patients with renal dysfunction (median eGFR 52 mL/min/1.73 m²), 29.2% experienced toxicity including leukopenia (10%), serious infections (8.3%), hepatotoxicity (7.5%), and pancytopenia (5%) 5
• Lower baseline eGFR was independently associated with higher toxicity risk (HR 0.938 per mL/min increase) 5
• Importantly, toxicity can occur even with normal serum methotrexate levels in patients with renal impairment 6

The Morbidity and Mortality Risk

The FDA black box warning emphasizes that "unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity" can occur with methotrexate 1. In renal dysfunction:

• Myelosuppression is the most important cause of methotrexate-associated death, and this risk increases significantly with renal dysfunction 4
• Toxicities include hemorrhagic enteritis, intestinal perforation, and multi-organ failure 1
• A case report describes fatal pancytopenia and multi-organ failure in a patient with CKD despite normal methotrexate levels 6

Why GFR 60 Specifically?

The GFR 60 threshold represents Stage 3 CKD where:

1. Drug clearance becomes significantly impaired - below this level, methotrexate elimination drops substantially
2. Risk-benefit ratio shifts unfavorably - the probability of serious toxicity outweighs therapeutic benefit
3. Alternative agents are available - azathioprine (first-line), mycophenolate mofetate, or rituximab can be used safely 2, 3, 7

The U.S. KDOQI commentary clarifies that while the guideline states GFR <60, "it would be more correct to state that methotrexate can be recommended for maintenance therapy, with dose reduction in patients with creatinine clearance 60 mL/min and avoidance of use with <30 mL/min" 7. However, given the narrow therapeutic index and unpredictable toxicity, the conservative GFR <60 cutoff is safer in clinical practice.

Critical Measurement Considerations

A major pitfall: Different GFR equations can yield significantly different values 8, 9:

• eGFR based on serum creatinine may overestimate true renal function compared to cystatin C-based equations
• When converting from creatinine-based to cystatin C-based eGFR, 6.4% of patients thought to have GFR >50 were reclassified to GFR 10-50, requiring dose adjustment 8
• Patients reclassified to worse CKD stages had significantly higher rates of methotrexate toxicity 8

Practical approach: Use the most conservative GFR estimate available, and consider cystatin C-based calculations in borderline cases.

What to Do Instead

When GFR falls below 60 mL/min/1.73 m²:

1. First-line alternative: Azathioprine 1-2 mg/kg/day (Grade 1B recommendation) 2, 3, 7

   • Check thiopurine S-methyltransferase levels first to avoid myelosuppression 7

2. Second-line: Mycophenolate mofetate up to 1g twice daily if azathioprine is not tolerated 2, 3, 7

3. For severe disease: Rituximab with corticosteroids 2, 3

The Bottom Line

The GFR <60 contraindication exists because methotrexate's renal elimination creates an unacceptable risk of life-threatening toxicity when kidney function is impaired. This is not a relative contraindication to be managed with "careful monitoring"—it is a hard stop based on pharmacokinetic principles, guideline consensus, and documented mortality risk. Safer, equally effective alternatives exist and should be used instead.